{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:35:50Z","timestamp":1790516150894,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T00:00:00Z","timestamp":1443571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.beha.2015.09.004","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T20:48:56Z","timestamp":1445287736000},"page":"217-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Long-term follow-up after purine analogue therapy in hairy cell leukaemia"],"prefix":"10.1016","volume":"28","author":[{"given":"Monica","family":"Else","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Dearden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Catovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2015.09.004_bib1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood.V13.7.609.609","article-title":"Leukemic reticuloendotheliosis","volume":"13","author":"Bouroncle","year":"1958","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.004_bib2","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.1984.2.12.1336","article-title":"Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin)","volume":"2","author":"Spiers","year":"1984","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.004_bib3","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1200\/JCO.1989.7.10.1533","article-title":"Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European organization for research and Treatment of Cancer Leukemia Cooperative Group","volume":"7","author":"Ho","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.004_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1200\/JCO.1991.9.2.243","article-title":"Pentostatin induces durable remissions in hairy cell leukemia","volume":"9","author":"Cassileth","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2015.09.004_bib5","first-page":"109","article-title":"Long term results with 2'deoxycoformycin in hairy cell leukemia","volume":"14","author":"Catovsky","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2015.09.004_bib6","first-page":"2037","article-title":"Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515","volume":"8","author":"Golomb","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2015.09.004_bib7","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1182\/blood.V84.12.4061.bloodjournal84124061","article-title":"Long-term follow-up of patients with hairy cell leukemia after treatment with 2-deoxycoformycin","volume":"84","author":"Kraut","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.004_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","article-title":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study","volume":"13","author":"Grever","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.004_bib9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","article-title":"Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine","volume":"322","author":"Piro","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2015.09.004_bib10","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/blood.V79.4.882.bloodjournal794882","article-title":"Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA)","volume":"79","author":"Estey","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.004_bib11","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood.V79.4.888.bloodjournal794888","article-title":"Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2_-deoxyadenosine (CdA): relation to opportunistic infections","volume":"79","author":"Juliusson","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.004_bib12","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1997.15.3.1138","article-title":"Treatment of hairy cell leukemia with cladribine: response, toxicity, and long term follow-up","volume":"15","author":"Hoffman","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.004_bib13","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.1998.16.9.3007","article-title":"Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients","volume":"16","author":"Cheson","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.004_bib14","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2015.09.004_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/10428194.2011.565093","article-title":"Long-term results for pentostatin and cladribine treatment of hairy cell leukemia","volume":"52","author":"Dearden","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2015.09.004_bib16","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2009-10-251645","article-title":"Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine","volume":"115","author":"Sigal","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.004_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11912-006-0055-z","article-title":"Hairy cell leukemia. [review]","volume":"8","author":"Dearden","year":"2006","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.beha.2015.09.004_bib18","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1002\/cncr.25243","article-title":"Hairy cell leukemia: evaluation of the long-term outcome in 121 patients","volume":"116","author":"Zinzani","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2015.09.004_bib19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else","year":"2009","journal-title":"Br J Haematol"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2015.09.004_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10428194.2011.568650","article-title":"Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence","volume":"52","author":"Else","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2015.09.004_bib21","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2011-04-351502","article-title":"Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia","volume":"118","author":"Ravandi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.004_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00277-014-2175-0","article-title":"Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases","volume":"94","author":"Leclerc","year":"2015","journal-title":"Ann Hematol"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2015.09.004_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/10428194.2011.565842","article-title":"Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy","volume":"52","author":"Juliusson","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2015.09.004_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/10428194.2011.570395","article-title":"Alternative methods of cladribine administration","volume":"52","author":"Lauria","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2015.09.004_bib25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2141.2011.08931.x","article-title":"Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Compiled on Behalf of the clinical Task Force of the British Committee for standards in Haematology","volume":"156","author":"Jones","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2015.09.004_bib26","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00277-014-2140-y","article-title":"Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia","volume":"93","author":"Cornet","year":"2014","journal-title":"Ann Hematol"},{"issue":"Suppl. 5","key":"10.1016\/j.beha.2015.09.004_bib27","doi-asserted-by":"crossref","first-page":"v100","DOI":"10.1093\/annonc\/mdv200","article-title":"Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Robak","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2015.09.004_bib28","first-page":"2981","article-title":"Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin","volume":"96","author":"Flinn","year":"2000","journal-title":"Blood"},{"issue":"2 Suppl. 5","key":"10.1016\/j.beha.2015.09.004_bib29","first-page":"32","article-title":"Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study","volume":"27","author":"Johnston","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.beha.2015.09.004_bib30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<352::AID-CNCR15>3.0.CO;2-8","article-title":"Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients","volume":"88","author":"Rafel","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2015.09.004_bib31","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1200\/JCO.2003.05.093","article-title":"Extended follow-up of patients with hairy cell leukemia after treatment with cladribine","volume":"21","author":"Goodman","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.004_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.leu.2402784","article-title":"Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients","volume":"17","author":"Maloisel","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2015.09.004_bib33","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/sj.leu.2403418","article-title":"An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine","volume":"18","author":"Jehn","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2015.09.004_bib34","first-page":"309","article-title":"Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine","volume":"89","author":"Zinzani","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2015.09.004_bib35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2005-01-0173","article-title":"Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience","volume":"106","author":"Chadha","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.004_bib36","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/cncr.21447","article-title":"Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years","volume":"104","author":"Else","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2015.09.004_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2013-06-508754","article-title":"Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series","volume":"123","author":"Rosenberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.004_bib38","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3109\/10428194.2013.827187","article-title":"Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)","volume":"55","author":"L\u00f3pez Rubio","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2015.09.004_bib39","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/bjh.12908","article-title":"Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia","volume":"166","author":"Cornet","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2015.09.004_bib40","article-title":"Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy","author":"Hacioglu","year":"2014","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2015.09.004_bib41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4103\/0971-5851.144988","article-title":"Hairy cell leukemia: a decade long experience of North Indian Hematology Center","volume":"35","author":"Somasundaram","year":"2014","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.beha.2015.09.004_bib42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1179\/102453312X13376952196331","article-title":"Treatment of hairy cell leukemia: long-term results in a developing country","volume":"17","author":"Ruiz-Delgado","year":"2012","journal-title":"Hematology"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2015.09.004_bib43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/10428190903142273","article-title":"Combination therapies to improve the long-term outcome in hairy cell leukemia","volume":"50","author":"Lauria","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2015.09.004_bib44","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias","volume":"51","author":"Ginaldi","year":"1998","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.beha.2015.09.004_bib45","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7326\/0003-4819-119-4-199308150-00005","article-title":"Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin","volume":"119","author":"Saven","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2015.09.004_bib46","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2009-03-212449","article-title":"Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior","volume":"114","author":"Forconi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.004_bib47","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/blood-2009-01-201731","article-title":"VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy","volume":"114","author":"Arons","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.004_bib48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.12839","article-title":"Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high-risk patients","volume":"166","author":"Garnache Ottou","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2015.09.004_bib49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2009-06-195370","article-title":"How I treat hairy cell leukemia","volume":"115","author":"Grever","year":"2010","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261500016X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261500016X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T20:03:35Z","timestamp":1599681815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169261500016X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S152169261500016X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2015.09.004","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725969421.793544950","asserted-by":"object"}]},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term follow-up after purine analogue therapy in hairy cell leukaemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2015.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}